Serum free light chains in patients with ST elevation myocardial infarction (STEMI): A possible correlation with left ventricle dysfunction.
Free light chains
Heart failure
Left ventricle dysfunction
STEMI
Journal
International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
received:
12
01
2019
revised:
25
05
2019
accepted:
10
06
2019
pubmed:
30
6
2019
medline:
26
6
2020
entrez:
30
6
2019
Statut:
ppublish
Résumé
Light chains are proteins produced by plasma cells, also called light chains kappa and lambda, are tied together with other proteins (heavy chains) to form the intact immunoglobulins or antibodies. Recent studies have shown a possible role of combined free light chains (cFLC) as an inflammatory marker in patients with chronic heart failure (HF). HF is a significant contributor to overall mortality in the community, but often patients with chronic HF also have chronic renal failure, which could alter the concentration of cFLC. We evaluated the FLC in patients with STEMI (n = 113), who were treated with primary angioplasty in the Cardiology Department of the University Hospital "Tor Vergata". For each patient during hospitalization we have determined blood concentration of cFLC, in addition to routine blood tests and we also performed an echocardiogram to evaluate cardiac function. We performed cFLC serum concentration in 113 patients with STEMI and observed that the cFLC concentration correlates with Left Ventricle Ejection Fraction (LVEF). We identified that the majority of patients (97%) who had one of the two positive light chains also had a reduced systolic function (LVEF <50%). For the first time in this paper we highlight the increase of serum free light chains concentrations in acute ischemic heart failure in patients with STEMI and without kidney failure. The cFLC could be proposed as a new biomarker for left ventricle dysfunction, further studies are required to confirm these results.
Sections du résumé
BACKGROUND
Light chains are proteins produced by plasma cells, also called light chains kappa and lambda, are tied together with other proteins (heavy chains) to form the intact immunoglobulins or antibodies. Recent studies have shown a possible role of combined free light chains (cFLC) as an inflammatory marker in patients with chronic heart failure (HF). HF is a significant contributor to overall mortality in the community, but often patients with chronic HF also have chronic renal failure, which could alter the concentration of cFLC.
METHODS
We evaluated the FLC in patients with STEMI (n = 113), who were treated with primary angioplasty in the Cardiology Department of the University Hospital "Tor Vergata". For each patient during hospitalization we have determined blood concentration of cFLC, in addition to routine blood tests and we also performed an echocardiogram to evaluate cardiac function.
RESULTS
We performed cFLC serum concentration in 113 patients with STEMI and observed that the cFLC concentration correlates with Left Ventricle Ejection Fraction (LVEF). We identified that the majority of patients (97%) who had one of the two positive light chains also had a reduced systolic function (LVEF <50%).
CONCLUSIONS
For the first time in this paper we highlight the increase of serum free light chains concentrations in acute ischemic heart failure in patients with STEMI and without kidney failure. The cFLC could be proposed as a new biomarker for left ventricle dysfunction, further studies are required to confirm these results.
Identifiants
pubmed: 31253526
pii: S0167-5273(19)30221-9
doi: 10.1016/j.ijcard.2019.06.016
pii:
doi:
Substances chimiques
Immunoglobulin Light Chains
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-34Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.